Centre of Influenza Research, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; The HKU-Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Centre of Influenza Research, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.
Antiviral Res. 2014 Jun;106:95-104. doi: 10.1016/j.antiviral.2014.03.019. Epub 2014 Apr 6.
Human disease caused by highly pathogenic avian influenza A (HPAI) (H5N1) is associated with fulminant viral pneumonia and mortality rates in excess of 60%. Acute respiratory syndrome (ARDS) has been found to be the most severe form of acute lung injury caused by H5N1 virus infection while cytokine dysregulation and viral replication are thought to contribute to its pathogenesis. In this study, the antiviral and anti-inflammatory effects of two indirubin derivatives: indirubin-3'-oxime (IM) and E804 on primary human peripherial blood-derived macrophages and type-I like pneumocytes (human alveolar epithelial cells) during influenza A (H5N1) virus infection were investigated. We found that both of the indirubin derivatives strongly suppress the pro-inflammatory cytokines including IP-10 (CXCL10), one of the key factors which contribute to the lung inflammation during H5N1 virus infection. In addition, we also demonstrated that the indirubin derivative delays the virus replication in the primary cell culture models. Our results showed that indirubin derivatives have a potential to be used as an adjunct to antiviral therapy for the treatment of severe human H5N1 disease.
人患高致病性禽流感(HPAI)(H5N1)可引起暴发性病毒性肺炎,死亡率超过 60%。已发现急性呼吸窘迫综合征(ARDS)是由 H5N1 病毒感染引起的最严重的急性肺损伤形式,而细胞因子失调和病毒复制被认为是其发病机制的原因。在这项研究中,研究了两种靛玉红衍生物:吲哚美辛-3'-肟(IM)和 E804 在甲型流感(H5N1)病毒感染期间对原代人外周血衍生的巨噬细胞和 I 型样肺细胞(人肺泡上皮细胞)的抗病毒和抗炎作用。我们发现这两种靛玉红衍生物均能强烈抑制促炎细胞因子,包括 IP-10(CXCL10),这是导致 H5N1 病毒感染期间肺部炎症的关键因素之一。此外,我们还证明了靛玉红衍生物可延迟原代细胞培养模型中的病毒复制。我们的研究结果表明,靛玉红衍生物具有作为辅助抗病毒治疗严重人类 H5N1 疾病的潜力。